



Media Contact

Casey Lassiter, 205 447-6410  
casey.lassiter@encompasshealth.com

April 26, 2018

Investor Relations Contact

Crissy Carlisle, 205 970-5860  
crissy.carlisle@encompasshealth.com

## Encompass Health reports results for first quarter 2018 and updates full-year 2018 guidance

BIRMINGHAM, Ala. - Encompass Health Corporation (NYSE: EHC), a national leader in post-acute care, offering facility-based and home-based patient care through its network of inpatient rehabilitation hospitals, home health agencies and hospice agencies, today reported its results of operations for the first quarter ended March 31, 2018.

“We’re off to a good start in 2018 as both segments generated strong volume, revenue, and earnings growth. Based on the strength of these results, we made upward adjustments to our full-year 2018 guidance ranges,” said Mark Tarr, President and Chief Executive Officer of Encompass Health. “We also made solid progress on our strategic initiatives during the first quarter including portfolio growth in both segments, implementation of our rebranding and name change, increasing clinical collaboration between our two segments, and the development of enhanced patient navigation and post-acute network management tools through the Post-Acute Innovation Center. Initiatives such as these serve to enhance our position as the post-acute provider of choice with healthcare systems, physicians, patients, and payors.”

### Consolidated results

	Q1 2018	Q1 2017	Growth	
			Dollars	Percent
	(In Millions, Except per Share Data)			
Net operating revenues	\$ 1,046.0	\$ 957.1	\$ 88.9	9.3%
Income from continuing operations attributable to Encompass Health per diluted share	0.85	0.70	0.15	21.4%
Adjusted earnings per share	0.93	0.70	0.23	32.9%
Cash flows provided by operating activities	216.3	180.8	35.5	19.6%
Adjusted EBITDA	223.3	200.8	22.5	11.2%
Adjusted free cash flow	170.2	147.5	22.7	15.4%

Revenue growth was driven by volume and pricing growth in the inpatient rehabilitation segment and volume growth in the home health and hospice segment. See the “Other Information” section of this release for discussion of the Company’s adoption of a new accounting standard for revenue recognition.

The increase in income from continuing operations attributable to Encompass Health per share and adjusted earnings per share resulted primarily from increased revenue and a lower effective tax rate resulting from income tax reform.

Growth in cash flows provided by operating activities and adjusted free cash flow resulted primarily from revenue growth and favorable working capital changes.

See attached supplemental information for calculations of non-GAAP measures and reconciliations to their most comparable GAAP measure.

### Inpatient rehabilitation segment results

	Q1 2018	Q1 2017	Growth	
			Dollars	Percent
<b>Net operating revenues:</b>				
	(In Millions)			
Inpatient	\$ 817.1	\$ 752.7	\$ 64.4	8.6 %
Outpatient and other	23.2	25.1	(1.9)	(7.6)%
<b>Total segment revenue</b>	<b>\$ 840.3</b>	<b>\$ 777.8</b>	<b>\$ 62.5</b>	<b>8.0 %</b>
	(Actual Amounts)			
Discharges	45,108	42,259	2,849	6.7 %
Same-store discharge growth				4.8 %
Net patient revenue per discharge	\$ 18,114	\$ 17,812	\$ 302	1.7 %
	(In Millions)			
Adjusted EBITDA	\$ 223.8	\$ 205.4	\$ 18.4	9.0 %

- *Revenue* - Revenue growth resulted from volume growth and an increase in net patient revenue per discharge. A heavy incidence of influenza at acute care hospitals and the timing of discharges around Easter and Passover contributed to discharge growth. Discharge growth from new stores resulted from the Company's joint ventures in Gulfport, Mississippi (April 2017), Westerville, Ohio (April 2017), and Jackson, Tennessee (July 2017), as well as a wholly owned hospital in Pearland, Texas (October 2017). Growth in net patient revenue per discharge primarily resulted from an increase in Medicare reimbursement rates and a year-over-year reduction in bad debt, which is now a component of revenue (see the "Other Information" section of this release).

The decrease in outpatient and other revenues primarily was due to the continued closures of hospital-based outpatient programs.

- *Adjusted EBITDA* - The increase in Adjusted EBITDA primarily resulted from revenue growth. Expense ratios in the first quarter of 2018 compared to the first quarter of 2017 benefited from a year-over-year reduction in bad debt, which is now a component of revenue (see the "Other Information" section of this release). Salaries and benefits as a percent of net operating revenues benefited from labor management and higher volumes. Other operating expenses as a percent of net operating revenues increased primarily due to increases in contract services.

## Home health and hospice segment results

	Q1 2018	Q1 2017	Growth	
			Dollars	Percent
<b>Net operating revenues:</b>			(In Millions)	
Home health	\$ 185.2	\$ 163.7	\$ 21.5	13.1 %
Hospice and other	20.5	15.6	4.9	31.4 %
<b>Total segment revenue</b>	<b>\$ 205.7</b>	<b>\$ 179.3</b>	<b>\$ 26.4</b>	<b>14.7 %</b>

Home Health Metrics				
(Actual Amounts)				
<b>Admissions</b>	33,855	30,810	3,045	9.9 %
Same-store admissions growth				7.4 %
<b>Episodes</b>	56,658	49,260	7,398	15.0 %
Same-store episode growth				12.7 %
<b>Revenue per episode</b>	<b>\$ 2,934</b>	<b>\$ 2,978</b>	<b>\$ (44)</b>	<b>(1.5)%</b>
			(In Millions)	
<b>Adjusted EBITDA</b>	<b>\$ 33.5</b>	<b>\$ 23.9</b>	<b>\$ 9.6</b>	<b>40.2 %</b>

- *Revenue* - Revenue growth was driven by volume growth. Revenue per episode was negatively impacted by an approximate \$4 million reserve for a Zone Program Integrity Contractor, or ZPIC, audit. Excluding this reserve, revenue per episode would have increased by 0.7% as changes in patient mix offset the impact of Medicare reimbursement rate cuts.

Hospice and other revenue increased primarily due to same-store volume growth and acquisitions in 2017.

- *Adjusted EBITDA* - Growth in Adjusted EBITDA primarily resulted from revenue growth and improvements in caregiver productivity and efficiency.

## Corporate general and administrative expenses

	Q1 2018	% of Consolidated Revenue	Q1 2017	% of Consolidated Revenue
General and administrative expenses, excluding stock-based compensation	\$ 34.0	3.3%	\$ 28.5	3.0%

- *General and administrative expenses* increased as a percent of consolidated revenue due to expenses associated with the Company's rebranding and name change. During the first quarter of 2018, the Company invested \$3.6 million in its rebranding and name change, all of which was included in general and administrative expenses. During the first quarter of 2017, the Company invested \$0.5 million in its rebranding and name change.

## 2018 guidance

Based on its results for the first quarter of 2018 and its current expectations for the remainder of 2018, the Company is increasing its full-year guidance ranges for 2018.

	Full-Year 2018 Guidance Ranges	
	Previous Guidance	Updated Guidance
	(In Millions, Except Per Share Data)	
Net operating revenues	\$4,080 to \$4,190	\$4,110 to \$4,210
Adjusted EBITDA	\$830 to \$850	\$845 to \$865
Adjusted earnings per share from continuing operations attributable to Encompass Health	\$3.25 to \$3.40	\$3.30 to \$3.45

The above guidance ranges are inclusive of the previously announced definitive agreement to acquire Camellia Healthcare, which is expected to close prior to June 1, 2018.

For additional considerations regarding the Company's 2018 guidance ranges, see the supplemental information posted on the Company's website at <http://investor.encompasshealth.com>. See also the "Other Information" section below for an explanation of why the Company does not provide guidance for comparable GAAP measures for Adjusted EBITDA and adjusted earnings per share.

### Earnings conference call and webcast

The Company will host an investor conference call at 9:00 a.m. Eastern Time on Friday, April 27, 2018 to discuss its results for the first quarter of 2018. For reference during the call, the Company will post certain supplemental information at <http://investor.encompasshealth.com>.

The conference call may be accessed by dialing 877 587-6761 and giving the pass code 7575309. International callers should dial 706 679-1635 and give the same pass code. Please call approximately ten minutes before the start of the call to ensure you are connected. The conference call will also be webcast live and will be available for on-line replay at <http://investor.encompasshealth.com> by clicking on an available link.

### About Encompass Health

As a national leader in post-acute care, Encompass Health (NYSE: EHC) offers both facility-based and home-based patient care through its network of inpatient rehabilitation hospitals, home health agencies and hospice agencies. With a national footprint that spans 127 hospitals and 236 home health & hospice locations in 36 states and Puerto Rico, the Company is committed to delivering high-quality, cost-effective care across the post-acute continuum. Driven by a set of shared values, Encompass Health is the result of the union between HealthSouth Corporation and Encompass Home Health & Hospice, and is ranked as one of Fortune's 100 Best Companies to Work For, as well as Modern Healthcare's Best Places to Work. For more information, visit [encompasshealth.com](http://encompasshealth.com), or follow us on Twitter and Facebook.

### Other information

The information in this press release is summarized and should be read in conjunction with the Company's Quarterly Report on Form 10-Q for the quarter ended March 31, 2018 (the "March 2018 Form 10-Q"), when filed, as well as the Company's Current Report on Form 8-K filed on April 26, 2018 (the "Q1 Earnings Form 8-K"), to which this press release is attached as Exhibit 99.1. In addition, the Company will post supplemental information today on its website at <http://investor.encompasshealth.com> for reference during its April 27, 2018 earnings call.

During the first quarter of 2018, the Company adopted a new accounting standard (ASC 606 - Revenue from Contracts with Customers) which clarifies the standards for recognizing revenue. The impact to the Company's financial reporting was that amounts previously presented as provision for doubtful became a

component of net operating revenues. This had the effect of reducing net operating revenues but was neutral to Adjusted EBITDA and adjusted earnings per share. The Company retrospectively adopted the new standard during the first quarter of 2018, which means previously reported quarterly and full-year results for 2017 have been updated to reflect the requirements of the new standard. For additional information, see the supplemental information posted on the Company's website at <http://investor.encompasshealth.com>.

The financial data contained in the press release and supplemental information include non-GAAP financial measures, including the Company's adjusted earnings per share, leverage ratio, Adjusted EBITDA, and adjusted free cash flow. Reconciliations to their most comparable GAAP measure, except with regard to non-GAAP guidance, are included below or in the Q1 Earnings Form 8-K. Readers are encouraged to review the "Note Regarding Presentation of Non-GAAP Financial Measures" included in the Q1 Earnings Form 8-K which provides further explanation and disclosure regarding the Company's use of these non-GAAP financial measures.

Excluding net operating revenues, the Company does not provide guidance on a GAAP basis because it is unable to predict, with reasonable certainty, the future impact of items that are deemed to be outside the control of the Company or otherwise non-indicative of its ongoing operating performance. Such items include government, class action, and related settlements; professional fees—accounting, tax, and legal; mark-to-market adjustments for stock appreciation rights; gains or losses related to hedging instruments; loss on early extinguishment of debt; adjustments to its income tax provision (such as valuation allowance adjustments and settlements of income tax claims); items related to corporate and facility restructurings; and certain other items the Company believes to be non-indicative of its ongoing operations. These items cannot be reasonably predicted and will depend on several factors, including industry and market conditions, and could be material to the Company's results computed in accordance with GAAP.

However, the following reasonably estimable GAAP measures for 2018 would be included in a reconciliation for Adjusted EBITDA if the other reconciling GAAP measures could be reasonably predicted:

- Interest expense and amortization of debt discounts and fees - estimate of \$147 million to \$157 million
- Amortization of debt-related items - approximately \$7 million

The Q1 Earnings Form 8-K and, when filed, the March 2018 Form 10-Q can be found on the Company's website at <http://investor.encompasshealth.com> and the SEC's website at [www.sec.gov](http://www.sec.gov).

**Encompass Health Corporation and Subsidiaries**  
**Condensed Consolidated Statements of Operations**  
(Unaudited)

	Three Months Ended March 31,	
	2018	2017
	(In Millions, Except per Share Data)	
Net operating revenues	\$ 1,046.0	\$ 957.1
Operating expenses:		
Salaries and benefits	570.2	530.1
Other operating expenses	141.2	127.8
Occupancy costs	18.6	17.9
Supplies	39.9	37.0
General and administrative expenses	61.1	36.5
Depreciation and amortization	45.9	45.2
Total operating expenses	<u>876.9</u>	<u>794.5</u>
Interest expense and amortization of debt discounts and fees	35.6	41.3
Other loss (income)	0.1	(1.0)
Equity in net income of nonconsolidated affiliates	(2.3)	(2.1)
Income from continuing operations before income tax expense	<u>135.7</u>	<u>124.4</u>
Provision for income tax expense	30.0	39.7
Income from continuing operations	<u>105.7</u>	<u>84.7</u>
Loss from discontinued operations, net of tax	(0.5)	(0.3)
<b>Net income</b>	<u>105.2</u>	<u>84.4</u>
Less: Net income attributable to noncontrolling interests	(21.4)	(17.6)
<b>Net income attributable to Encompass Health</b>	<u>\$ 83.8</u>	<u>\$ 66.8</u>
<b>Weighted average common shares outstanding:</b>		
Basic	<u>97.8</u>	<u>88.8</u>
Diluted	<u>99.4</u>	<u>99.0</u>
<b>Earnings per common share:</b>		
<b>Basic earnings per share attributable to Encompass Health common shareholders:</b>		
Continuing operations	\$ 0.86	\$ 0.75
Discontinued operations	(0.01)	—
Net income	<u>\$ 0.85</u>	<u>\$ 0.75</u>
<b>Diluted earnings per share attributable to Encompass Health common shareholders:</b>		
Continuing operations	\$ 0.85	\$ 0.70
Discontinued operations	(0.01)	—
Net income	<u>\$ 0.84</u>	<u>\$ 0.70</u>
Cash dividends per common share	<u>\$ 0.25</u>	<u>\$ 0.24</u>
<b>Amounts attributable to Encompass Health common shareholders:</b>		
Income from continuing operations	\$ 84.3	\$ 67.1
Loss from discontinued operations, net of tax	(0.5)	(0.3)
Net income attributable to Encompass Health	<u>\$ 83.8</u>	<u>\$ 66.8</u>

**Encompass Health Corporation and Subsidiaries**  
**Condensed Consolidated Balance Sheets**  
(Unaudited)

	<u>March 31,</u> <u>2018</u>	<u>December 31,</u> <u>2017</u>
	(In Millions)	
<b>Assets</b>		
<b>Current assets:</b>		
Cash and cash equivalents	\$ 86.4	\$ 54.4
Restricted cash	69.4	62.4
Accounts receivable	463.1	472.1
Other current assets	89.6	113.3
Total current assets	708.5	702.2
Property and equipment, net	1,554.3	1,517.1
Goodwill	1,973.1	1,972.6
Intangible assets, net	396.1	403.1
Deferred income tax assets	68.5	63.6
Other long-term assets	239.1	235.1
Total assets	\$ 4,939.6	\$ 4,893.7
<b>Liabilities and Shareholders' Equity</b>		
<b>Current liabilities:</b>		
Current portion of long-term debt	\$ 32.7	\$ 32.3
Accounts payable	83.1	78.4
Accrued expenses and other current liabilities	456.2	406.8
Total current liabilities	572.0	517.5
Long-term debt, net of current portion	2,544.4	2,545.4
Other long-term liabilities	183.8	185.3
	3,300.2	3,248.2
<b>Commitments and contingencies</b>		
Redeemable noncontrolling interests	198.6	220.9
<b>Shareholders' equity:</b>		
Encompass Health shareholders' equity	1,197.0	1,181.7
Noncontrolling interests	243.8	242.9
Total shareholders' equity	1,440.8	1,424.6
Total liabilities and shareholders' equity	\$ 4,939.6	\$ 4,893.7

Encompass Health Corporation and Subsidiaries  
Condensed Consolidated Statements of Cash Flows  
(Unaudited)

	Three Months Ended March 31,	
	2018	2017
	(In Millions)	
<b>Cash flows from operating activities:</b>		
Net income	\$ 105.2	\$ 84.4
Loss from discontinued operations, net of tax	0.5	0.3
Adjustments to reconcile net income to net cash provided by operating activities—		
Depreciation and amortization	45.9	45.2
Stock-based compensation	26.1	8.0
Deferred tax (benefit) expense	(3.0)	49.0
Other, net	1.6	2.5
Change in assets and liabilities, net of acquisitions—		
Accounts receivable	8.3	(3.6)
Other assets	14.2	(16.4)
Accounts payable	1.3	(1.7)
Accrued payroll	(9.5)	(3.0)
Other liabilities	26.4	16.5
Net cash used in operating activities of discontinued operations	(0.7)	(0.4)
Total adjustments	110.6	96.1
<b>Net cash provided by operating activities</b>	<b>216.3</b>	<b>180.8</b>
<b>Cash flows from investing activities:</b>		
Purchases of property and equipment	(59.9)	(41.2)
Acquisitions of businesses, net of cash acquired	(0.6)	(16.4)
Other, net	(0.1)	8.5
<b>Net cash used in investing activities</b>	<b>(60.6)</b>	<b>(49.1)</b>
<b>Cash flows from financing activities:</b>		
Borrowings on revolving credit facility	95.0	55.0
Payments on revolving credit facility	(95.0)	(122.0)
Repurchases of common stock, including fees and expenses	—	(18.1)
Dividends paid on common stock	(25.4)	(22.2)
Purchase of equity interests in consolidated affiliates	(65.1)	—
Proceeds from exercising stock warrants	—	26.6
Distributions paid to noncontrolling interests of consolidated affiliates	(15.4)	(11.5)
Other, net	(10.8)	(14.1)
<b>Net cash used in financing activities</b>	<b>(116.7)</b>	<b>(106.3)</b>
<b>Increase in cash, cash equivalents, and restricted cash</b>	<b>39.0</b>	<b>25.4</b>
<b>Cash, cash equivalents, and restricted cash at beginning of period</b>	<b>116.8</b>	<b>101.4</b>
<b>Cash, cash equivalents, and restricted cash at end of period</b>	<b>\$ 155.8</b>	<b>\$ 126.8</b>
<b>Reconciliation of Cash, Cash Equivalents, and Restricted Cash</b>		
Cash and cash equivalents at beginning of period	\$ 54.4	\$ 40.5
Restricted cash at beginning of period	62.4	60.9
Cash, cash equivalents, and restricted cash at beginning of period	\$ 116.8	\$ 101.4
Cash and cash equivalents at end of period	\$ 86.4	\$ 61.2
Restricted cash at end of period	69.4	65.6
Cash, cash equivalents, and restricted cash at end of period	\$ 155.8	\$ 126.8

**Encompass Health Corporation and Subsidiaries**  
**Supplemental Information**  
**Earnings Per Share**

	Three Months Ended March 31,	
	2018	2017
	(In Millions, Except Per Share Data)	
<b>Adjusted EBITDA</b>	\$ 223.3	\$ 200.8
Depreciation and amortization	(45.9)	(45.2)
Interest expense and amortization of debt discounts and fees	(35.6)	(41.3)
Stock-based compensation expense	(26.1)	(8.0)
Noncash (loss) gain on disposal of assets	(0.8)	0.5
	<u>114.9</u>	<u>106.8</u>
<b>Certain items non-indicative of ongoing operating performance:</b>		
Transaction costs	(1.0)	—
SARs mark-to-market impact on noncontrolling interests	1.0	—
Change in fair market value of equity securities	(0.6)	—
<b>Pre-tax income</b>	<u>114.3</u>	<u>106.8</u>
Income tax expense	(30.0)	(39.7)
<b>Income from continuing operations <sup>(1)</sup></b>	<u>\$ 84.3</u>	<u>\$ 67.1</u>
<b>Basic shares</b>	<u>97.8</u>	<u>88.8</u>
<b>Diluted shares</b>	<u>99.4</u>	<u>99.0</u>
<b>Basic earnings per share <sup>(1)</sup></b>	<u>\$ 0.86</u>	<u>\$ 0.75</u>
<b>Diluted earnings per share <sup>(1)</sup></b>	<u>\$ 0.85</u>	<u>\$ 0.70</u>

<sup>(1)</sup> Income from continuing operations attributable to Encompass Health

**Encompass Health Corporation and Subsidiaries**  
**Supplemental Information**  
**Adjusted Earnings Per Share**

	Q1	
	2018	2017
<b>Earnings per share, as reported</b>	<b>\$ 0.85</b>	<b>\$ 0.70</b>
Adjustments, net of tax:		
Mark-to-market adjustments for stock appreciation rights	0.08	0.02
Transaction costs	0.01	—
Income tax adjustments	—	(0.03)
<b>Adjusted earnings per share<sup>(1)</sup></b>	<b>\$ 0.93</b>	<b>\$ 0.70</b>

(1) Adjusted EPS may not sum due to rounding.

**Encompass Health Corporation and Subsidiaries**  
**Supplemental Information**  
**Adjusted Earnings Per Share**

For the Three Months Ended March 31, 2018

	Adjustments					As Adjusted
	As Reported	Mark-to-Market Adjustment for Stock Compensation Expense	Income Tax Adjustments	Transaction Costs	Change in Fair Market Value of Equity Securities	
	(In Millions, Except Per Share Amounts)					
<b>Adjusted EBITDA<sup>(1)</sup></b>	\$ 223.3	\$ —	\$ —	\$ —	\$ —	\$ 223.3
Depreciation and amortization	(45.9)	—	—	—	—	(45.9)
Interest expense and amortization of debt discounts and fees	(35.6)	—	—	—	—	(35.6)
Stock-based compensation	(26.1)	11.6	—	—	—	(14.5)
Loss on disposal of assets	(0.8)	—	—	—	—	(0.8)
Transaction costs	(1.0)	—	—	1.0	—	—
SARs mark-to-market impact on noncontrolling interests	1.0	(1.0)	—	—	—	—
Change in fair market value of equity securities	(0.6)	—	—	—	0.6	—
<b>Income from continuing operations before income tax expense</b>	114.3	10.6	—	1.0	0.6	126.5
Provision for income tax expense	(30.0)	(3.0)	(0.2)	(0.3)	(0.2)	(33.7)
<b>Income from continuing operations attributable to Encompass Health</b>	\$ 84.3	\$ 7.6	\$ (0.2)	\$ 0.7	\$ 0.4	\$ 92.8
Add: Interest, amortization, and loss on extinguishment of convertible debt, net of tax	—					—
<b>Numerator for diluted earnings per share</b>	\$ 84.3					\$ 92.8
<b>Diluted earnings per share from continuing operations<sup>(2)</sup></b>	\$ 0.85	\$ 0.08	\$ —	\$ 0.01	\$ —	\$ 0.93
<b>Diluted shares used in calculation</b>	99.4					

(1) Reconciliation to GAAP provided on page 13

(2) Adjusted EPS may not sum across due to rounding.

Encompass Health Corporation and Subsidiaries  
Supplemental Information  
Adjusted Earnings Per Share

For the Three Months Ended March 31, 2017

	Adjustments			
	As Reported	Mark-to-Market Adjustment for Stock Appreciation Rights	Income Tax Adjustments	As Adjusted
	(In Millions, Except Per Share Amounts)			
<b>Adjusted EBITDA<sup>(1)</sup></b>	\$ 200.8	\$ —	\$ —	\$ 200.8
Depreciation and amortization	(45.2)	—	—	(45.2)
Interest expense and amortization of debt discounts and fees	(41.3)	—	—	(41.3)
Stock-based compensation	(8.0)	3.3	—	(4.7)
Gain on disposal of assets	0.5	—	—	0.5
Income from continuing operations before income tax expense	106.8	3.3	—	110.1
Provision for income tax expense	(39.7)	(1.3)	(2.6)	(43.6)
Income from continuing operations attributable to Encompass Health	\$ 67.1	\$ 2.0	\$ (2.6)	\$ 66.5
Add: Interest on convertible debt, net of tax	2.5			2.5
Numerator for diluted earnings per share	<u>\$ 69.6</u>			<u>\$ 69.0</u>
Diluted earnings per share from continuing operations <sup>(2)</sup>	<u>\$ 0.70</u>	<u>\$ 0.02</u>	<u>\$ (0.03)</u>	<u>\$ 0.70</u>
Diluted shares used in calculation	<u>99.0</u>			

(1) Reconciliation to GAAP provided on page 13

(2) Adjusted EPS may not sum across due to rounding.

**Encompass Health Corporation and Subsidiaries**  
**Supplemental Information**  
**Reconciliation of Net Income to Adjusted EBITDA**

	Three Months Ended March 31,	
	2018	2017
	(In Millions)	
<b>Net income</b>	\$ 105.2	\$ 84.4
Loss from discontinued operations, net of tax, attributable to Encompass Health	0.5	0.3
Net income attributable to noncontrolling interests	(21.4)	(17.6)
Provision for income tax expense	30.0	39.7
Interest expense and amortization of debt discounts and fees	35.6	41.3
Depreciation and amortization	45.9	45.2
Net noncash loss (gain) on disposal of assets	0.8	(0.5)
Stock-based compensation expense	26.1	8.0
Transaction costs	1.0	—
SARs mark-to-market impact on noncontrolling interests	(1.0)	—
Change in fair market value of equity securities	0.6	—
<b>Adjusted EBITDA</b>	<u>\$ 223.3</u>	<u>\$ 200.8</u>

**Reconciliation of Segment Adjusted EBITDA to Income from Continuing Operations Before Income Tax Expense**

	Three Months Ended March 31,	
	2018	2017
	(In Millions)	
<b>Total segment Adjusted EBITDA</b>	\$ 257.3	\$ 229.3
General and administrative expenses	(61.1)	(36.5)
Depreciation and amortization	(45.9)	(45.2)
(Loss) gain on disposal of assets	(0.8)	0.5
Interest expense and amortization of debt discounts and fees	(35.6)	(41.3)
Net income attributable to noncontrolling interests	21.4	17.6
SARs mark-to-market impact on noncontrolling interests	1.0	—
Change in fair market value of equity securities	(0.6)	—
<b>Income from continuing operations before income tax expense</b>	<u>\$ 135.7</u>	<u>\$ 124.4</u>

**Encompass Health Corporation and Subsidiaries**  
**Supplemental Information**  
**Reconciliation of Net Cash Provided by Operating Activities to Adjusted EBITDA**

	<b>Three Months Ended March 31,</b>	
	<b>2018</b>	<b>2017</b>
	<b>(In Millions)</b>	
<b>Net cash provided by operating activities</b>	<b>\$ 216.3</b>	<b>\$ 180.8</b>
Interest expense and amortization of debt discounts and fees	35.6	41.3
Equity in net income of nonconsolidated affiliates	2.3	2.1
Net income attributable to noncontrolling interests in continuing operations	(21.4)	(17.6)
Amortization of debt-related items	(1.0)	(3.5)
Distributions from nonconsolidated affiliates	(1.2)	(2.1)
Current portion of income tax expense (benefit)	33.0	(9.3)
Change in assets and liabilities	(40.7)	8.2
Cash used in operating activities of discontinued operations	0.7	0.4
Transaction costs	1.0	—
SARs mark-to-market impact on noncontrolling interests	(1.0)	—
Change in fair market value of equity securities	0.6	—
Other	(0.9)	0.5
<b>Consolidated Adjusted EBITDA</b>	<b>\$ 223.3</b>	<b>\$ 200.8</b>

**Encompass Health Corporation and Subsidiaries**  
**Supplemental Information**  
**Reconciliation of Net Cash Provided by Operating Activities to Adjusted Free Cash Flow**

	<b>Three Months Ended March 31,</b>	
	<b>2018</b>	<b>2017</b>
	<b>(In Millions)</b>	
<b>Net cash provided by operating activities</b>	\$ 216.3	\$ 180.8
Impact of discontinued operations	0.7	0.4
<b>Net cash provided by operating activities of continuing operations</b>	<b>217.0</b>	<b>181.2</b>
Capital expenditures for maintenance	(36.1)	(22.2)
Distributions paid to noncontrolling interests of consolidated affiliates	(15.4)	(11.5)
<b>Items non-indicative of ongoing operations:</b>		
Transaction costs and related assumed liabilities	0.4	—
Cash paid for SARs exercise	4.3	—
<b>Adjusted free cash flow</b>	<b>\$ 170.2</b>	<b>\$ 147.5</b>

For the three months ended March 31, 2018, net cash used in investing activities was \$60.6 million and primarily resulted from capital expenditures. Net cash used in financing activities during the three months ended March 31, 2018 was \$116.7 million and primarily resulted from purchasing one-third of the Rollover Shares held by members of the home health and hospice management team, cash dividends paid on common stock, and distributions paid to noncontrolling interests of consolidated affiliates.

For the three months ended March 31, 2017, net cash used in investing activities was \$49.1 million and resulted primarily from capital expenditures and acquisitions of businesses. Net cash used in financing activities during the three months ended March 31, 2017 was \$106.3 million and resulted primarily from net debt payments, cash dividends paid on common stock, repurchases of common stock in the open market, and distributions paid to noncontrolling interests of consolidated affiliates offset by proceeds from the exercising of stock warrants.

**Encompass Health Corporation and Subsidiaries**  
**Forward-Looking Statements**

*Statements contained in this press release which are not historical facts, such as those relating to financial guidance and assumptions, balance sheet and cash flow plans, and anticipated acquisitions, are forward-looking statements. In addition, Encompass Health, through its senior management, may from time to time make forward-looking public statements concerning the matters described herein. All such estimates, projections, and forward-looking information speak only as of the date hereof, and Encompass Health undertakes no duty to publicly update or revise such forward-looking information, whether as a result of new information, future events, or otherwise. Such forward-looking statements are necessarily estimates based upon current information, involve a number of risks and uncertainties, and relate to, among other things, future events, Encompass Health's plan to repurchase its debt or equity securities, dividend strategies, effective income tax rates, its business strategy, its financial plans, its future financial performance, its projected business results or model, its ability to return value to shareholders, its projected capital expenditures, its leverage ratio, its acquisition opportunities, and the impact of future legislation or regulation. Actual events or results may differ materially from those anticipated in these forward-looking statements as a result of a variety of factors. While it is impossible to identify all such factors, factors which could cause actual events or results to differ materially from those estimated by Encompass Health include, but are not limited to, the price of Encompass Health's common stock as it affects the Company's willingness and ability to repurchase shares and the financial and accounting effects of any repurchases; any adverse outcome of various lawsuits, claims, and legal or regulatory proceedings involving Encompass Health, including its pending DOJ and HHS-OIG investigations and any matters related to yet undiscovered issues, if any, in acquired operations; Encompass Health's ability to attract and retain key management personnel; any adverse effects on Encompass Health's stock price resulting from the integration of acquired operations; potential disruptions, breaches, or other incidents affecting the proper operation, availability, or security of Encompass Health's information systems, including unauthorized access to or theft of patient, business associate, or other sensitive information or inability to provide patient care because of system unavailability as well as unforeseen issues, if any, related to integration of acquired systems; the ability to successfully integrate acquired operations, including realization of anticipated tax benefits, revenues, and cost savings, minimizing the negative impact on margins arising from changes in staffing and other operating practices, and avoidance of unforeseen exposure to liabilities; Encompass Health's ability to successfully complete and integrate de novo developments, acquisitions, investments, and joint ventures consistent with its growth strategy; increases in Medicare audit activity resulting in additional unpaid reimbursement claims and an increase in the backlog of appealed claims denials; changes, delays in (including in connection with resolution of Medicare payment reviews or appeals), or suspension of reimbursement for Encompass Health's services by governmental or private payors; changes in the regulation of the healthcare industry at either or both of the federal and state levels, including as part of national healthcare reform and deficit reduction (such as the home health groupings model and other payment system reforms); competitive pressures in the healthcare industry and Encompass Health's response thereto; Encompass Health's ability to obtain and retain favorable arrangements with third-party payors; Encompass Health's ability to control costs, particularly labor and employee benefit costs, including group medical expenses; adverse effects resulting from coverage determinations made by Medicare Administrative Contractors regarding its Medicare reimbursement claims and lengthening delays in Encompass Health's ability to recover improperly denied claims through the administrative appeals process on a timely basis; Encompass Health's ability to adapt to changes in the healthcare delivery system, including involvement in coordinated care initiatives or programs that may arise with its referral sources; Encompass Health's ability to attract and retain nurses, therapists, and other healthcare professionals in a highly competitive environment with often severe staffing shortages and the impact on Encompass Health's labor expenses from potential union activity and staffing shortages; general conditions in the economy and capital markets, including any instability or uncertainty related to armed conflict or an act of terrorism, governmental impasse over approval of the United States federal budget, an increase to the debt ceiling, or an international sovereign debt crisis; the increase in the costs of defending and insuring against alleged professional liability claims and Encompass Health's ability to predict the estimated costs related to such claims; the impact of the ongoing rebranding and name change initiative on existing operations, including the ability to maintain or grow patient referrals as well as the associated costs of rebranding; and other factors which may be identified from time to time in Encompass*

**Encompass Health Corporation and Subsidiaries  
Forward-Looking Statements**

*Health's SEC filings and other public announcements, including Encompass Health's Form 10-K for the year ended December 31, 2017 and Form 10-Q for the quarter ended March 31, 2018, when filed.*